Advances in Therapy for Hormone Receptor (HR)-Positive, Human Epidermal Growth Factor 2 (HER2)-Negative Advanced Breast Cancer Patients Who Have Experienced Progression After Treatment with CDK4/6 Inhibitors

Background: Elucidating the clinical features of metastatic breast cancer (MBC) patients with an exceptionally favorable prognosis may offer insights to improve survival more typical patients. Methods: We collected comprehensive real-world data on clinicopathologic characteristics, treatments, and outcomes 110 consecutive MBC who survived for over ten years from warehouse Samsung Medical Center...

background and objectives: the most prevalent malignancy among women is known to be breast cancer (bc). several factors contribute to determining tumor prognosis and treatment strategies. in this study, the frequency and relevance of these factors are discussed. materials and methods: this cross-sectional study was carried out on 214 patients with bc, who referred to the cancer institute of im...

BACKGROUND To review the efficacy of chemotherapy and human epidermal growth factor receptor 2 (HER2)-targeted therapy when used in addition to hormonal therapy for the optimal management of estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-positive (HER2+) breast cancer. DESIGN Literature published from January 2003 to March 2008 was reviewed to assess the use of chem...

Many breast cancer deaths result from tumors acquiring resistance to available therapies. Thus, new therapeutic agents are needed for targeting drug-resistant breast cancers. Drug-refractory breast cancers include HER2+ tumors that have acquired resistance to HER2-targeted antibodies and kinase inhibitors, and "Triple-Negative" Breast Cancers (TNBCs) that lack the therapeutic targets Estrogen R...

Approximately 50% of HER2-negative breast cancers (BC) show HER2-low expression. It is unclear however whether BC should be considered an individual biologic entity, prognostically distinct from HER2-zero BC. Data were collected institutional database including all consecutive patients with who underwent surgery at Dana-Farber Brigham Cancer Center 1/2016 to 3/2021. Tumors defined as if they ha...

HER2-positive breast cancer is one of the most common types female around world. This review summarizes information and results HER2 -positive trials compares their with standards in Bosnia Herzegovina. It done based on a literature search PubMed Google Scholar. analyzed trastuzumab as golden treatment standard for treatments. Trastuzumab monoclonal anti-human epidermal growth factor receptor a...

Efficient treatment of disseminated ovarian cancer (OC) is challenging due to its heterogeneity and chemoresistance. Overexpression human epidermal growth factor receptor 2 (HER2) epithelial cell adhesion molecule (EpCAM) in approx. 30% 70% cancers, respectively, allows for co-targeted treatment. The clinical efficacy the monoclonal antibody trastuzumab patients with HER2-positive breast, gastr...

The HER2 receptor tyrosine kinase is a driver oncogene in many human cancers, including breast and gastric cancer. Under physiologic levels of expression, HER2 heterodimerizes with other members of the EGF receptor/HER/ErbB family, and the HER2-HER3 dimer forms one of the most potent oncogenic receptor pairs. Previous structural biology studies have individually crystallized the kinase domains ...

We have previously shown that the HER2-specific affibody molecule (Z(HER2∶342))₂ inhibits proliferation of SKBR-3 cells. Here, we continue to investigate its biological effects in vitro by studying receptor dimerization and clonogenic survival following irradiation. We found that (Z(HER2∶342))₂ sensitizes the HER2-overexpressing cell line SKBR-3 to ionizing radiation. The survival after exposur...